European Journal of Cardiovascular Medicine

Acute pancreatitis is one of the severe disease due to acute inflammation of pancreas. Acute pancreatitis is a disease with a wide spectrum of severity, complications, and outcome. Unfortunately, we don't have much data regarding the epidemiology of this disease but the international stats tell us that the incidence of acute pancreatitis in the UK is 56 cases per 100,000 persons per year [1], while in the US over 220,000 hospital admissions annually are attributed to acute pancreatitis [2]. An epidemiologic study that utilized UK and European data demonstrated an increasing incidence in all-cause acute pancreatitis [3]. The incidence of acute pancreatitis was also noted to increase with age [3]. The male population had an incidence that was 10%–30% higher than females [4]. Of all hospital admissions with acute pancreatitis, 20%–30% of patients have a severe course [1], while severe life-threatening complications will develop in 25% of these patients [4]. The mortality in severe acute pancreatitis can be as high as 30% [2], but the overall mortality in acute pancreatitis is estimated to be 5% [1]. Gallstones remain the most common cause for acute pancreatitis. Gallstone-related acute pancreatitis accounts for approximately half of all UK cases, while up to 25% of acute pancreatitis cases can be attributed to alcohol [1]. To date, there is no drug available to treat acute pancreatitis, so most care is supportive. With this limitation, most clinical management guidelines [5,6], emphasize an approach that includes predicting and establishing the severity of acute pancreatitis to triage patients to appropriate levels of care; administering supportive care, including intravenous hydration and enteral nutrition; and treating the underlying cause and complications by appropriate use of urgent endoscopic retrograde cholangiopancreatography (ERCP), early cholecystectomy, targeted use of antibiotics, and interventions for pancreatic fluid collections in the later stages, usually after 4 weeks.

There are various diagnostic tests and criteria scoring systems are available to diagnose acute pancreatitis but none of them has been labeled as gold standard. A list of various inflammatory markers has also been tried for example C-reactive protein (CRP), Procalcitonin, Lactate dehydrogenase, Albumin, etc, have been tried. CRP, now a days being commonly use as a marker of inflammation as its radially available and comparatively economical than others inflammatory markers. C-reactive protein exhibits elevated expression during inflammatory conditions such as rheumatoid arthritis, some cardio-vascular diseases, and infection [7]. As an acute-phase protein, the plasma concentration of CRP deviates by at least 25% during inflammatory disorders [8]. The highest concentrations of CRP are found in serum, with some bacterial infections increasing levels up to 1000-fold [9]. However, when the stimuli ends, CRP values decrease exponentially over 18–20 h, close to the half-life of CRP [10]. CRP plasma levels increase from around 1 μg/mL to over 500 μg/mL within 24–72 h of severe tissue damage such as trauma and progressive cancer [11]. IL-6 is reported to be the main inducer of CRP gene expression, with IL-1 enhancing the effect [12]. However, although IL-6 is necessary for CRP gene induction, it is not sufficient to achieve this alone [13].

The rationale of this study is to diagnose the severity of acute pancreatitis using a single test ratio rather than evaluating through a criteria system like Ranson's Criteria which includes eleven different parameters and more over half of them are sent after 48 h of admission. It will be in great benefit for the patient if we could establish a single test ratio system to predict the severity of acute pancreatitis

This study was done at our hospital from January 1, 2024, to December 31, 24. The study adhered to the tenets of the Declaration of Helsinki, and approval from the institutional research ethics board was obtained for the study.

This retrospective, observational study was conducted at general surgery department of a new teaching tertiary care hospital in Central India. Non-probability consecutive sampling method was used to recruit all the study participants diagnosed with acute pancreatitis on clinical and radiological grounds and admitted to intensive care unit (ICU). CRP/albumin ratio is a combination of markers for systemic inflammation and nutritional status which is calculated by dividing the CRP level (mg/L) with the serum albumin level (g/L). Taking population mean of 2.90 and standard deviation of 3.02 reported by Zhao et al. [14], a sample size of 205 is calculated by using a W.H.O sample size calculator (7.1: Estimating a population mean) in which we used 5% as margin of error, and 95% as confidence interval (CI). However, we took 450 patients for best results.

All those patients with age group 16–80 years who were diagnosed with acute pancreatitis and admitted subsequently to ICU were included in our study. Those who were having autoimmune diseases, multiple co-morbidities, or any chronic inflammatory conditions were excluded from the study. STROCSS guidelines were adhered while reporting the findings of the study [15].

For data collection, A proforma was designed to have two sections; first section covered demographic details including name (as optional), age (in years), gender, and other clinical (abdominal pain, physical examination findings) and biochemical characteristics (serum amylase/lipase) available from the medical records of the patients. Second section determines the serum albumin and CRP levels correlating with disease severity at admission and comparison with CT severity score. An expert radiology team reported the findings of Computerized Tomography (CT) scan, polygonal descriptive of which is represented in Supplementary Fig. 1; where CT severity score was reported on a scale of 1–10 with 10 being most severe. Score above 7 was determined as severe pancreatitis, while up to 2 was labeled as mild form; and moderate disease is between 3 and 6 severity score. Data was collected after laboratory evaluation is done through serum samples for CRP and albumin sent for the enrolled patients at admission. CRP was analyzed via Cobas (C-311) using immunoturbidimetric assay (Roche/Hitachi Cobas C systems).

After collection of data the analyses was conducted by using Statistical Package for Social Science (IBM SPSS) software, version 25.0 (Armonk, NY, USA). The Chi-square test was used to compare categorical variables, and if found limited, Fisher's exact test will be applied. Receiver operating characteristic (ROC) curves was used to evaluate the diagnostic performance of CRP/albumin ratio in determining the severity of pancreatitis. Sensitivity refers to the probability of a positive test, conditioned on truly being positive (TP), calculated as TP/TP + FN; Specificity refers to the probability of a negative test, conditioned on truly being negative (TN), calculated as TN/TN + FP; and diagnostic accuracy: the proportion of correct diagnosis found by a diagnostic test, calculated as TP + TN/TN + FP + FN + TP was given priority. Lastly, Delong's was applied for statistical comparisons between CRP/albumin ratio and CRP along as predictive marker of severity of pancreatitis. MedCalc Statistical Software Ltd (free trial version) was used for applying Delong's test [16].

The study included 450 patients diagnosed with acute pancreatitis with 60% males, and 40–50 years of age group more frequently represented (27%). A total of 186 individuals had severe pancreatitis (CT severity score≥7). Other complications included peri-pancreatic fluid (94%), ascites (78%), pleural effusion (73%), multi-organ failure (72.4%), and duodenal swelling/thickening (25%) as shown in Table 1. All of these complications were expectedly higher in severe pancreatitis as shown in Table 2.

ROC analysis for CRP/albumin ratio is shown in Table 3. Optimum cut-off value of 4.35 was determined for CRP/albumin ratio via highest Youden index at which the sensitivity to predict severe pancreatitis was 87% as compared to 82% for CRP alone. Although this comparison is not statistically indifferent at Delong's test (P-value: 0.22) with similar diagnostic accuracy of 76% vs 74%, however the ratio had higher AUC (0.827) and higher negative predictive value (88%). Interestingly, patients with elevated CRP/albumin ratio had higher odds with complications like multi-organ failure 2.31 [1.3–4.2], duodenal thickening 2.25 [1.2–4.2], and ascites 2.90 [1.5–5.6] as shown in Table 4.

Higher measures of distribution were noticed among bimodal age groups (16–30 years and then 41–60 years), while 31–40 years and extreme age group (61–80 years) had the lowest 95th percentiles for CRP/albumin ratio.

Table 1 showing Baseline clinical characteristics and radiological findings of the study inclusions (n = 450).

Table 2: showing classification between mild, moderate and severe based on CT severity score.

Table 3: Receiver Operating Characteristics (ROC) analysis CRP/Alb ratio for severity of pancreatitis.

Table 4: Multivariable regression for pancreatitis complications with elevated CRP/Alb ratio.

Previous studies have shown CRP/albumin ratio as an important prognostic marker in acute pancreatitis. Mustafa K. et al., in 2017, concluded in his study that the CRP/albumin ratio is a novel but promising, easy-to-measure, repeatable, non-invasive inflammation-based prognostic score in acute pancreatitis [17]. Previously, CRP/albumin ratio has been utilized to predict the prognosis in emergency surgical patients undergoing intensive care [18]. While, one study conducted on animals determined role of CRP/albumin ratio in survival of acute pancreatitis [19]. Kalafat et al. determined a cut-off value for CRP/albumin ratio of 1.08 as highly specific (97%) for diagnosis of acute pancreatitis [20]. Another study determined a direct correlation of Ranson's score with CRP/albumin ratio. Zhao et al. found CRP/Albumin ratio independently associated with mortality in acute pancreatitis patients [14].

Some studies also shown weak association of CRP levels alone at admission and 48 h after hospital stay with complicated acute pancreatitis [21]. While modified CT severity index was considered most predictive for severity of the disease. But Li Y et al. found significant association of CRP levels with mortality [22]. While Han S et al. studied CRP and albumin levels separately and found not only significant correlations with Ranson's score but also the accuracy of Ranson's scale was improved with elevated CRP and decreased albumin levels [23]. This justified our analysis of predicting severity with CRP/Albumin ratio rather than CRP levels alone. Lastly, CRP/albumin ratio was considered a good prognostic marker in predicting severe acute pancreatitis with significantly moderate correlations with all severity scores and hospitalization period [24]. Similar findings were reported Yilmaz and his colleagues [25]. Even accounting for other inflammatory markers like Ferritin, CRP/albumin ratio stands out in predicting severity of the disease and mortality in acute pancreatitis [26].

There are several important factors that could have contributed to limitations of this study. This is a single-center evaluation with a small sample size hence limiting the generalizability of the results. The external validity is also compromised with lack of patient's data with respect to their prognosis, ICU data with parameters (like APACHE-II), further management and disease outcomes. While, internal validity is compromised with the introduction of collider bias when two variables have the same denominator i.e., CRP levels; as part of the ratio also increases the likelihood of comparative ROC analysis been insignificant.

Although, the statistical difference between CRP/albumin ratio and CRP levels alone isn't much, but overall, the sensitivity and accuracy are increased to predict severe pancreatitis by bringing albumin into the picture. Such non-invasive and readily available parameters should be relied upon admission to risk stratify the patients suffering from pancreatitis.

1. Pancreatitis N.I.C.E. National Institute for Clinical Excellence; London, UK: 2016. Diagnosis and Management Draft Scope for Consultation.
2. Whitcomb D.C. Acute pancreatitis. N. Engl. J. Med. 2006;354(20):2142–2150.
3. Yadav D., Lowenfels A.B. Trends in the epidemiology of the first attack of acute pancreatitis. Pancreas. 2006;33(4):323–330.
4. Toouli J., Brooke-Smith M., Bassi C., Carr-Locke D., Telford J., Freeny P., et al. Guidelines for the management of acute pancreatitis. J. Gastroenterol. Hepatol. 2002;17:515–539.
5. Tenner S., Baillie J., DeWitt J., Vege S.S. American College of Gastroenterology guideline: management of acute pancreatitis. Am. J. Gastroenterol. 2013;108:1400–1415.
6. Working Group IAP/APA Acute Pancreatitis Guidelines IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13:e1.
7. Du Clos T.W., Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol. Res. 2004;30(3):261–277.
8. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999;340(6):448–454.
9. Thompson D., Pepys M.B., Wood S.P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7(2):169–177.
10. Ridker P.M. Clinical application of C-reactive protein for cardiovascular dis-ease detection and prevention. Circulation. 2003;107:363–369.
11. Ciubotaru I., Potempa L.A., Wander R.C. Production of modified C-reactive protein in U937-derived macrophages. Exp. Biol. Med. 2005;230(10):762–770.
12. Szalai A.J., van Ginkel F.W., Dalrymple S.A., Murray R., McGhee J.R., Volankis J.E. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J. Immunol. 1998;160(11):5294–5299.
13. Weinhold B., Bader A., Valeria P.O.L.I., Rütehr U. Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem. J. 1997;325(3):617–621.
14. Zhao Z., Yu Y., Xie R., Yang K., Xu D., Li L., et al. Prognostic value of the creatinine-albumin ratio in acute pancreatitis debridement. BMC Surg. 2020;20:322.
15. Mathew G., Agha R., for the STROCSS Group Strocss 2021: strengthening the Reporting of cohort, cross-sectional and case-control studies in Surgery. Int. J. Surg. 2021;96
16. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
17. Kaplan M., Ates I., Akpinar M.Y., Yuksel M., Kuzu U.B., Kacar S., et al. Predictive value of C-reactive protein/albumin ratio in acute pancreatitis. Hepatobiliary Pancreat. Dis. Int. 2017;16(4):424–430.
18. Yilmaz P.O., Karacan E. The effects of C-reactive protein/albumin ratio and hematologic parameters on predicting the prognosis for emergency surgical patients in intensive care. Ulus Travma Acil Cerrahi Derg. 2021;27(1):67–72.
19. Gori E., Pierini A., Lippi I., Ceccherini G., Perondi F., Marchetti V. Evaluation of C-reactive protein/albumin ratio and its relationship with survival in dogs with acute pancreatitis. N. Z. Vet. J. 2020;68(6):345–348.
20. Kalafat U.M., Dogan S., Bildik B., Dorter M., Can D., Cander B. Predictive and prognostic value of C-reactive protein/albumin and neutrophil/lymphocyte ratio in the patients diagnosed with acute pancreatitis in emergency department. Asian J Med Health. 2020;18(4):24–32.
21. Ahmad R., Bhatti K.M., Ahmed M., et al. C-reactive protein as a predictor of complicated acute pancreatitis: reality or a myth? Cureus. 2021;13(11)
22. Li Y., Zhao Y., Feng L., et al. Comparison of the prognostic values of inflammation markers in patients with acute pancreatitis: a retrospective cohort study. BMJ Open. 2017;7
23. Han S., Ye J., Liu R., Chen W., Feng Z. The role of CRP or albumin with ranson scale in predicting severe acute pancreatitis mortality risk. Int. J. Clin. Exp. Med. 2019;12(8):10531–10536.
24. Gokden Y., Kutlu O. Predictive value of red cell distribution width and C reactive protein/albumin ratio in determining severe acute pancreatitis. Ann Med Res. 2021;27(3):971–976.
25. Yılmaz E.M., Kandemir A. Significance of red blood cell distribution width and C-reactive protein/albumin levels in predicting prognosis of acute pancreatitis. Ulus Travma Acil Cerrahi Derg. 2018;24:528–531.
26. Behera M.K., Mishra D., Sahu M.K., et al. C-reactive protein/albumin and ferritin as predictive markers for severity and mortality in patients with acute pancreatitis. Przegląd Gastroenterol. 2022:1–7.